Follow-up of phase I trial of adalimumab and rosiglitazone in FSGS: III. Report of the FONT study group.

BMC Nephrology
Alexandra PeyserHoward Trachtman

Abstract

Patients with resistant primary focal segmental glomerulosclerosis (FSGS) are at high risk of progression to chronic kidney disease stage V. Antifibrotic agents may slow or halt this process. We present outcomes of follow-up after a Phase I trial of adalimumab and rosiglitazone, antifibrotic drugs tested in the Novel Therapies in Resistant FSGS (FONT) study. 21 patients--12 males and 9 females, age 16.0 +/- 7.5 yr, and estimated GFR (GFRe) 121 +/- 56 mL/min/1.73 m2--received adalimumab (n = 10), 24 mg/m2 every 14 days or rosiglitazone (n = 11), 3 mg/m2 per day for 16 weeks. The change in GFRe per month prior to entry and after completion of the Phase I trial was compared. 19 patients completed the 16-week FONT treatment phase. The observation period pre-FONT was 18.3 +/- 10.2 months and 16.1 +/- 5.7 months after the study. A similar percentage of patients, 71% and 56%, in the rosiglitazone and adalimumab cohorts, respectively, had stabilization in GFRe, defined as a reduced negative slope of the line plotting GFRe versus time without requiring renal replacement therapy after completion of the FONT treatment period (P = 0.63). Nearly 50% of patients with resistant FSGS who receive novel antifibrotic agents may have a legacy effe...Continue Reading

References

Apr 1, 1995·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·J J RydelM M Schwartz
Sep 9, 2000·Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association·E AlexopoulosM Papadimitriou
Jul 31, 2004·Journal of the American Society of Nephrology : JASN·Micky J ChunEdmund J Lewis
Mar 8, 2006·Pediatric Nephrology : Journal of the International Pediatric Nephrology Association·Marcelo M AbrantesEduardo A Oliveira
Mar 10, 2007·Pediatric Nephrology : Journal of the International Pediatric Nephrology Association·Robert P Woroniecki, Jeffrey B Kopp
Aug 21, 2007·Clinical Journal of the American Society of Nephrology : CJASN·Sundararaman SwaminathanFernando C Fervenza
Aug 21, 2007·Clinical Journal of the American Society of Nephrology : CJASN·Lesley A StevensAndrew S Levey
Oct 4, 2007·Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association·Martin TidmanIan Jones
Feb 5, 2008·QJM : Monthly Journal of the Association of Physicians·O MoranneUNKNOWN GN-Progress Study Group
Sep 12, 2008·The New England Journal of Medicine·Rury R HolmanH Andrew W Neil
Sep 12, 2008·The New England Journal of Medicine·Rury R HolmanDavid R Matthews
Oct 10, 2008·The New England Journal of Medicine·John Chalmers, Mark E Cooper
Dec 17, 2008·Clinical Journal of the American Society of Nephrology : CJASN·Melanie S JoyHoward Trachtman
Jan 23, 2009·Journal of the American Society of Nephrology : JASN·George J SchwartzSusan L Furth
May 14, 2009·Vascular Health and Risk Management·Anthony H Barnett
Aug 20, 2009·Current Medicinal Chemistry·E Esposito, S Cuzzocrea
Sep 5, 2009·Clinical Chemistry and Laboratory Medicine : CCLM·Ariana Aguiar SoaresSandra Pinho Silveiro
Nov 26, 2009·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·Melanie S JoyHoward Trachtman

❮ Previous
Next ❯

Citations

Nov 27, 2010·Pediatric Nephrology : Journal of the International Pediatric Nephrology Association·Rasheed GbadegesinMichelle Winn
Jun 3, 2011·Science Translational Medicine·Andrew C Chan
Apr 28, 2012·Pediatric Nephrology : Journal of the International Pediatric Nephrology Association·Martin BitzanElena Torban
Jul 19, 2012·Pediatric Nephrology : Journal of the International Pediatric Nephrology Association·Moin A Saleem
Mar 19, 2016·BioMed Research International·Andreas KronbichlerJae Il Shin
Mar 1, 2012·Nutrition, Metabolism, and Cardiovascular Diseases : NMCD·D Bolignano, C Zoccali
Feb 24, 2015·Advances in Chronic Kidney Disease·Laura Malaga-DieguezHoward Trachtman
Aug 3, 2016·The Journal of Clinical Investigation·Christopher E PedigoAlessia Fornoni
Oct 27, 2018·Expert Opinion on Investigational Drugs·Rossella SiligatoDomenico Santoro
Oct 23, 2010·Clinical Journal of the American Society of Nephrology : CJASN·Ellen T McCarthyVirginia J Savin
Aug 31, 2013·Clinical Journal of the American Society of Nephrology : CJASN·Bhadran BoseUNKNOWN Toronto Glomerulonephritis Registry
Mar 1, 2013·Expert Review of Clinical Immunology·Claudio Ponticelli, Giorgio Graziani
Dec 7, 2013·American Journal of Physiology. Renal Physiology·Ruochen CheAihua Zhang
Apr 10, 2017·Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association·Stephen P McAdoo, Charles D Pusey
Oct 5, 2016·Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association·Caroline Platt, Richard J Coward
Dec 12, 2020·Kidney International·Amanda J Clark, Samir M Parikh

❮ Previous
Next ❯

Methods Mentioned

BETA
biopsy

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.